ReNeuron Group plc (RENE) Ordinary Shares
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
ReNeuron reaches exosome research milestone
4 September 2023 11:10
(Sharecast News) - UK-based biotechnology company ReNeuron Group, which specialises in stem cell-derived exosome technologies, announced significant advancements in the field of exosome research on Monday.
-
Director dealings: Reneuron CFO makes share purchase
24 January 2023 14:44
(Sharecast News) - Reneuron revealed on Tuesday that chief financial officer John Hawkins had acquired 100,000 ordinary shares in the AIM-listed stem cell technologies group.
-
ReNeuron shares tumble after first-half results
2 December 2022 12:47
(Sharecast News) - Stem-cell-derived exosome technology specialist ReNeuron Group reported first-half revenue of £0.44m on Friday, up from £0.06m year-on-year, related to income from partner-funded...
-
ReNeuron enters cancer therapy collaboration with UCL
26 October 2021 14:02
(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of...
-
Director dealings: Reneuron Group non-executive makes share purchase
21 October 2021 16:40
(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.
-
ReNeuron treats first Oxford patient as part of expanded study
18 October 2021 09:14
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the...
-
ReNeuron upbeat on positive data from Spain collaboration
11 October 2021 11:51
(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery...
-
ReNeuron gets approval to restart RP clinical study
1 October 2021 10:33
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa...
Company announcements Announcements
-
Appointment of Administrators
20 March 2024 15:43
ReNeuron Group
-
Intention to Appoint Administrators
20 March 2024 12:30
ReNeuron Group
-
Block Listing Review & Total Voting Rights
1 March 2024 07:00
ReNeuron Group
-
Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
27 November 2023 08:53
ReNeuron Group
-
Interim Results for the six months ended 30 Sept
8 November 2023 07:01
ReNeuron Group
-
ReNeuron presents in vivo data at Cell 2023
8 November 2023 07:00
ReNeuron Group
-
R&D Update
4 September 2023 07:00
ReNeuron Group
-
Block Listing Review & Total Voting Rights
1 September 2023 07:00
ReNeuron Group
-
Director declaration
29 August 2023 07:00
ReNeuron Group
-
Result of AGM
22 August 2023 10:34
ReNeuron Group
-
Notice of AGM
24 July 2023 17:20
ReNeuron Group
-
Share Purchase by Chief Financial Officer
12 July 2023 11:57
ReNeuron Group
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.